National Institute on Drug Abuse (NIDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).
National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.
National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.
Top-decile sponsor footprint
National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
335 total, page 3 of 7
Ph1 Marinol Interaction Study - Part 1 - 1
NCT00438139
The Neural Basis of Cue-Elicited Cigarette Craving and Its Control
NCT01048957
Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia
NCT00218374
Ph1 Marinol Interaction Study - Part 2 - 1
NCT00490269
Evaluating Alternative Aftercare Models for Ex-offenders
NCT01586689
The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215
NCT01034800
Screening Protocol for the Evaluation of Potential Research Subjects
NCT01036971
Screening Protocol for the Evaluation of Research Participants
NCT01036217
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
NCT01037075
Rivastigmine For Methamphetamine Dependent Individuals
NCT00158210
Efficacy of NicVAX in Smokers Who Want to Quit Smoking
NCT00318383
Antagonist-Elicited Cannabis Withdrawal
NCT01041170
Study of Smoking Abstinence
NCT01035632
Topiramate for the Treatment of Methamphetamine Dependence - 1
NCT00345371
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
NCT01034020
Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia
NCT01036568
Strategies to Help Adult ED Patients Quit Smoking
NCT00297466
Emergency Department Initiated Tobacco Treatment (EDITT)
NCT00252902
Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
NCT01603992
Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients
NCT00295308
Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2
NCT00135785
Smoking and Alcohol Initiation
NCT00271843
Effect of Functional Genetic Polymorphisms on Brain Morphology and Function
NCT01035723
A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches
NCT00134927
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
NCT00158145
Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2
NCT00158158
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1
NCT00265265
Impact of Smoking Cessation on Sleep - 5
NCT00132821
Effect of Clonidine on Responses to Imagery Scripts
NCT00318760
Smoking Treatment of Prisoners
NCT00110630
Metabolic Effects of Cocaine
NCT00451230
Cognitive Task Development and Implementation for Functional MRI Studies
NCT01036685
Drug Use Prevention Among Girls Through a Mother-Daughter Intervention
NCT00310258
Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence
NCT00304707
Addition of Naltrexone to Methadone Taper
NCT00135759
Reward Processing in Cocaine Addiction
NCT01036074
Dopamine Function and Reward Processing In Schizophrenia
NCT01035996
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
NCT00218517
Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine
NCT00777569
Effectiveness of Bupropion in Treating Marijuana Dependent Individuals
NCT00142870
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia
NCT01046526
Tramadol to Reduce Opioid Withdrawal Symptoms
NCT00142896
Nicotine Lozenge to Reduce Smokeless Tobacco Use
NCT00218283
Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking
NCT00248118
Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics
NCT00247689
Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals
NCT00218049
Atomoxetine for the Treatment of Cannabis Dependence
NCT00167297
Modafinil for the Treatment of Cocaine Dependence - 1
NCT00100100
Baclofen for the Treatment of Cocaine Dependence - 1
NCT00082485
Abuse Potential of Buprenorphine/Naloxone
NCT00149539
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 121 |
| Phase 3 | 14 |
| Phase 4 | 16 |
What is open in the National Institute on Drug Abuse (NIDA) pipeline
14 recruiting of 335 indexed (4% open); 292 completed (87%).
Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).
Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide
Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 335 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Genentech · 332 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Akebia Therapeutics · 4% recruiting · 24 trials
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this National Institute on Drug Abuse (NIDA) page
335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.
- 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets.Report a data error.